Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial
Importance: The PANOVA-3 trial demonstrated the survival benefit and tolerability of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel, but understanding the impact of TTFields therapy on quality of life (QoL) and pain is important for clinical decision-making. Objective: To analyze the impact of TTFields therapy concomitant with gemcitabine and nab-paclitaxel on QoL and pain outcomes using prospective data from PANOVA-3. Design, Setting, and Participants: This is a prespecified secondary analysis of PANOVA-3, which was a global, open-label, multicenter, phase 3 randomized clinical trial in adult patients with previously untreated locally advanced unresectable pancreatic adenocarcinoma (LA-PAC). A total of 571 patients were randomized between May 1, 2018, and March 31, 2023, with follow-up completed October 31, 2024. Data analysis was performed from November 2024 to May 2025. Intervention: Patients were randomized 1:1 to receive either TTFields therapy (150 kHz) with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) were administered intravenously on days 1, 8, and 15 of 28-day cycles. Duration of follow-up was 18 months. Main Outcomes and Measures: QoL was measured using the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire and the 26-item pancreatic cancer module. End points were mean changes from baseline QoL scores, deterioration-free survival of QoL, and time to opioid use. An analysis of pain medication use was performed post hoc. Results: At baseline, 562 patients (median [IQR] age, 67 [31-90] years; 295 [52.5%] female), including 279 of 285 patients in the TTFields plus gemcitabine and nab-paclitaxel arm and 283 of 286 patients in the gemcitabine and nab-paclitaxel arm, completed the EORTC QLQ-C30 questionnaire. Global health status was stable during the 26-month follow-up in both study arms. Digestive symptoms, pain, and pancreatic pain were improved from 2 months after treatment initiation throughout treatment and follow-up in the TTFields plus gemcitabine and nab-paclitaxel arm. TTFields plus gemcitabine and nab-paclitaxel was associated with longer deterioration-free survival for global health status than gemcitabine and nab-paclitaxel alone (median [IQR], 7.1 [3.5-14.8] vs 5.7 [2.3-11.5] months; hazard ratio [HR], 0.77; 95% CI, 0.61-0.97; P = .02). Longer deterioration-free survival was also observed for most items on the digestive symptoms scales (indigestion and altered bowel habit were similar between the 2 arms). Median (IQR) deterioration-free survival was significantly longer with TTFields plus gemcitabine and nab-paclitaxel for pain (10.1 [4.0-20.9] vs 7.4 [3.5-14.5] months; HR, 0.70; 95% CI, 0.54-0.89; P = .003) and pancreatic pain (14.7 [6.2-46.2] vs 10.2 [5.6-18.2] months; HR, 0.69; 95% CI, 0.52-0.90; P = .006) as was median time to opioid use in the modified intention-to-treat population (9.3 [3.9-18.6] vs 6.7 [1.1-16.3] months; HR, 0.72; 95% CI, 0.55-0.93; P = .01). Conclusions and Relevance: This secondary analysis of a randomized clinical trial found that TTFields therapy with gemcitabine and nab-paclitaxel improved QoL and provided clinically meaningful benefits in pain outcomes compared with gemcitabine and nab-paclitaxel alone. This study's results suggest that TTFields therapy with gemicitabine and nab-paclitaxel is practice-changing for patients with unresectable LA-PAC. Trial Registration: ClinicalTrials.gov Identifier: NCT03377491.
Authors
- Andrew Hendifar
- Higinia Rosa Cardenes (ORCID: https://orcid.org/0000-0001-6559-1807)
- Arsen Osipov (ORCID: https://orcid.org/0000-0002-9000-7040)
- Anup Kasi (ORCID: https://orcid.org/0000-0002-4305-5701)
- Daniel Rausch (ORCID: https://orcid.org/0000-0002-1901-3659)
- Anand Mahadevan (ORCID: https://orcid.org/0000-0003-3555-4217)
- Ashiq Masood (ORCID: https://orcid.org/0000-0002-1848-1178)
- Douglas Orr
- Joanna Amy Kolodney
- Kynan Feeney
- Bohuslav Melichar (ORCID: https://orcid.org/0000-0002-5474-6866)
- Jason Tache
- Mohit Narang (ORCID: https://orcid.org/0000-0002-8701-6210)
- Mark D. Kochenderfer
- Samer Shihabi
- Joseph Stilwill
- Sumana Nagireddy
- Panagiotis Valilis
- Trevor M. Feinstein
- Judith D. Sears
- ANTHONY SHIELDS
- Vincent J. Picozzi (ORCID: https://orcid.org/0009-0002-3493-7769)
- Timothy K. Huyck
- Makoto Ueno (ORCID: https://orcid.org/0000-0003-4480-0029)
- Lucjan Stanislaw Wyrwicz (ORCID: https://orcid.org/0000-0003-0808-6892)
- Hassan A. Hatoum (ORCID: https://orcid.org/0000-0001-7553-1963)
- Hani M. Babiker (ORCID: https://orcid.org/0000-0002-9368-6296)
- Henrik Illum
- Christelle de la Fouchardière (ORCID: https://orcid.org/0000-0003-2291-5693)
- Thomas Theodor Werner Seufferlein (ORCID: https://orcid.org/0000-0003-3259-0810)
- Benjamin L. Schlechter (ORCID: https://orcid.org/0000-0002-1529-3278)
- Emil Lou (ORCID: https://orcid.org/0000-0002-1607-1386)
- Tomislav Dragovich (ORCID: https://orcid.org/0000-0002-1569-2172)
- Andrea J. Bullock (ORCID: https://orcid.org/0000-0001-7143-0225)
- Philip Philip
- Deepti Behl (ORCID: https://orcid.org/0000-0002-8247-5055)
- Scott McKenney
- Teresa Mercade Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Peter J. Van Veldhuizen (ORCID: https://orcid.org/0000-0001-7140-4246)
- Kannan Thanikachalam (ORCID: https://orcid.org/0000-0001-5379-8966)
- Maen Abdelrahim (ORCID: https://orcid.org/0000-0002-6631-5035)
- Nadia N. Ramdin
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
- Cusnir Mike
- Jaswinder Singh
- Yixing Jiang (ORCID: https://orcid.org/0000-0002-3569-014X)
- Warren S. Brenner
- Carlos Becerra (ORCID: https://orcid.org/0009-0006-7735-8010)
- Ali Tasneem (ORCID: https://orcid.org/0000-0001-6441-4083)
- Sreenivasa Rao Chandana (ORCID: https://orcid.org/0000-0001-5390-9937)
- Sudhir Manda
- P. A. Philip
- Nicholas Alfred Blondin
- Venu Gopal Bathini
- Alexander Rosemurgy
- Anna Niewiaroska
- Hao Chunyi
- WooJin Lee
- Jin Gang
- Audrey Kam
- Robert Marsh
- James Reeves (ORCID: https://orcid.org/0009-0003-7251-3307)
- Sharona Ross
- Joshua Raff
- Jennifer De Los Santos (ORCID: https://orcid.org/0009-0002-8337-7913)
- WILLIAM SMALL
- Marisa Hill
- Francis Arena
- Marc Uemura
- Paul DeRose
- Javier Gallego
- David Spigel
- Rachna Shroff
- David Einspahr
- Mary Peters
- Herbert Newton
- Michael Anderson
- Garrett Green
- Sunil Gandhi
- John Hamm
- Andrew Coveler
- Lucas Wong
- Joseph Ye
- Steven DiBiase
- Ajit Maniam
- Donald Richards
- Joanna Bendell
- Richard Siegel
- PANOVA-3 study investigators
- Marc Matrana
- James Wang
- Fadi Braiteh
- John Russell
Institutions
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Virginia Mason Medical Center (US)
- Harvard University (US)
- Wayne State University (US)
- Henry Ford Hospital (US)
- St John of God Murdoch Hospital (AU)
- Peking University Cancer Hospital (CN)
- Centre Léon Bérard (FR)
- University Hospital Olomouc (CZ)
- Hospital Clínic de Barcelona (ES)
- Changhai Hospital (CN)
- Hospital General Universitario de Elche (ES)
- National Cancer Center (KR)
- University of Kansas Medical Center (US)
- Mayo Clinic in Florida (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University Hospital Ulm (DE)
- Kanagawa Cancer Center (JP)
- Baptist MD Anderson Cancer Center (US)
- Palacký University Olomouc (CZ)
- KU Leuven (BE)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.41241
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00